Trials / Active Not Recruiting
Active Not RecruitingNCT05610319
Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 446 (estimated)
- Sponsor
- McMaster University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faricimab | Faricimab will be administered via intravitreal injection. |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2022-11-09
- Last updated
- 2026-04-17
Locations
46 sites across 4 countries: United States, Australia, Canada, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05610319. Inclusion in this directory is not an endorsement.